The United States Patent and Trademark Office (USPTO) has granted patent US12584844B2 to BostonGene Corporation. This patent covers novel methods, systems, and computer-readable storage media for characterizing subjects with cancer. Specifically, it details techniques for immunoprofiling a cancer subject's peripheral blood leukocytes to determine their prognosis and likelihood of responding to immunotherapy.

This patent grant is primarily relevant for entities involved in cancer diagnostics, research, and the development of immunotherapies. While it does not impose direct compliance obligations, it signifies intellectual property protection for specific diagnostic and prognostic methods in oncology. Companies operating in this space should be aware of this patent to ensure their own research and development activities do not infringe upon the granted claims.